MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...
Pharmaceutical Technology on MSN6d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...
AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...
The Parainfluenza Virus Infection market is expected to surge due to the disease's increasing prevalence and awareness during ...
The shift towards new cell culture–based flu vaccine production has been dealt a blow as MedImmune of Gaithersburg, Maryland, puts its manufacturing efforts on hold. The AstraZeneca subsidiary ...
The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to ...
Executive Vice President, R&D, MedImmune, Gaithersburg, Maryland, USA. Prior to joining Medimmune in 2001, Peter Kiener, D. Phil., spent 18 years with the Pharmaceutical Research Division of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback